<i>In silico</i> Analysis of Interactions between HLA-B*58:01 and Allopurinol-related Compounds

DOI Web Site 2 Citations 8 References
  • Osabe Makoto
    Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University,
  • Tohkin Masahiro
    Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University,
  • Hirayama Noriaki
    Institute of Glycoscience, Tokai University

Bibliographic Information

Other Title
  • アロプリノール関連化合物とHLA-B*58:01相互作用の<i>in silico</i>解析
  • In silico analysis of interactions between HLA-B*58:01 and allopurinol-related compounds

Abstract

Allopurinol, the most traditional and widely used medication for hyperuricemia and gout, has been reported as a common cause of severe cutaneous adverse reactions. Allopurinol is rapidly and extensively metabolized to oxipurinol. At least six allopurinol-related impurities have been reported to be contained in allopurinol. It is of interest to identify the compound which is likely to be responsible to the adverse reactions. Since a strong association between allopurinol-induced adverse reactions and HLA-B*58:01 has been observed, binding of allopurinol-related compounds to HLA-B*58:01 must be important for the onset of the adverse reactions. In this study, using the three-dimensional structure of HLA-B*58:01 constructed by homology modeling, the binding modes and affinities between allopurinol-related compounds and HLA-B*58:01 were simulated by docking simulations. The results have indicated that the adverse reactions of allopurinol should be due very largely to oxipurinol. The results also suggested that the concentrations of several impurities currently approved by the United States Pharmacopeia should be strictly monitored not to exceed the limits because they may strongly bind to HLA-B*58:01 and possibly leading to more severe adverse reactions.

Journal

Citations (2)*help

See more

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top